Patents by Inventor Andrew Sharpe
Andrew Sharpe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130018057Abstract: A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: ApplicationFiled: November 11, 2010Publication date: January 17, 2013Applicant: UCB PHARMA S.A.Inventors: Roland Bürli, Alan Findlay Haughan, Mîzio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
-
Publication number: 20130012517Abstract: A series of quinoline and quinoxaline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: ApplicationFiled: November 11, 2010Publication date: January 10, 2013Applicant: UCB PHARMA S.A.Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
-
Patent number: 8324204Abstract: A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: GrantFiled: June 4, 2007Date of Patent: December 4, 2012Assignee: UCB Pharma SAInventors: Rikki Peter Alexander, Stuart Bailey, Stephen Brand, Daniel Christopher Brookings, Julien Alistair Brown, Alan Findlay Haughan, Natasha Kinsella, Christopher Lowe, Stephen Robert Mack, William Ross Pitt, Marianna Dilani Richard, Andrew Sharpe, Laura Jane Tait
-
Publication number: 20120277166Abstract: The invention relates to an isolated, synthetic or recombinant ?-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.Type: ApplicationFiled: May 25, 2011Publication date: November 1, 2012Applicant: XENOME LIMITEDInventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe
-
Publication number: 20120095005Abstract: A series of substituted pyrazolo[1,5-?][1,3,5]triazine and pyrazolo[1,5-?j-pyrimidine derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I).Type: ApplicationFiled: May 19, 2010Publication date: April 19, 2012Applicant: UCB PHARMA S.A.Inventors: Daniel Rees Allen, Julien Alistair Brown, Roland Burli, Alan Findlay Haughan, Barry John Langham, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
-
Publication number: 20120077815Abstract: A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: ApplicationFiled: February 11, 2010Publication date: March 29, 2012Applicant: UCB PHARMA S.A.Inventors: Daniel Rees Allen, Julien Alistair Brown, Roland Burli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe
-
Publication number: 20120053167Abstract: A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: ApplicationFiled: March 2, 2010Publication date: March 1, 2012Applicant: UCB PHARMA, S.A.Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, David John Nash, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe
-
Publication number: 20120028503Abstract: An adaptor is shaped for allowing use of a micro SIM card in a mini SIM card implemented device. An adaptor body is shaped like a micro SIM card and may include a cutout region for receiving a micro SIM card therein.Type: ApplicationFiled: December 9, 2010Publication date: February 2, 2012Inventors: Cameron Alan Holmes, William Andrew Sharpe, Odette Kim Holmes
-
Publication number: 20110105508Abstract: A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: ApplicationFiled: December 17, 2008Publication date: May 5, 2011Applicant: UCB PHARMA, S.A.Inventors: Daniel Rees Allen, George Martin Buckley, Roland Bürli, John Richard Davenport, Natasha Kinsella, Christopher James Lock, Christopher Lowe, Stephen Robert Mack, William Ross Pitt, Andrew James Ratcliffe, Marianna Dilani Richard, Verity Margaret Sabin, Andrew Sharpe, Laura Jane Tait, Graham John Warrelow, Sophie Caroline Williams
-
Publication number: 20100305066Abstract: A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: ApplicationFiled: June 4, 2007Publication date: December 2, 2010Applicant: UCB PHARMA S.A.Inventors: Rikki Peter Alexander, Stuart Bailey, Stephen Brand, Daniel Christopher Brookings, Julien Alistair Brown, Alan Findlay Haughan, Natasha Kinsella, Christopher Lowe, Stephen Robert Mack, William Ross Pitt, Marianna Dilani Richard, Andrew Sharpe, Laura Jane Tait
-
Patent number: 7752742Abstract: Systems and methods for providing a sealed container having a reduced pressure atmosphere are disclosed. The container is suitable for housing an infrared detector array. Outgassing can be enhanced by adding features to solder preforms that maintain pathways for gasses to more readily exit the container prior to sealing thereof. Getters can be used to mitigate undesirable gases within the sealed container. One or more bolometers can be used to determine if the sealed container is leaking. A vacuum positioning fixture can be used to assemble the components of the infrared detector assembly and to place the infrared detector assemblies into a vacuum chamber. The cost of manufacturing such infrared detector assemblies may be reduced and the reliability thereof enhanced.Type: GrantFiled: August 19, 2008Date of Patent: July 13, 2010Assignee: Flir Systems, Inc.Inventors: Paul Schweikert, William J. Parrish, Andrew Sharpe, Vu L. Nguyen, Marco Scussat
-
Publication number: 20090275498Abstract: The invention relates to an isolated, synthetic or recombinant ?-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.Type: ApplicationFiled: November 2, 2007Publication date: November 5, 2009Applicant: The University of QueenslandInventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe
-
Patent number: 7470904Abstract: Systems and methods for providing a sealed container having a reduced pressure atmosphere are disclosed. The container is suitable for housing an infrared detector array. Outgassing can be enhanced by adding features to solder preforms that maintain pathways for gasses to more readily exit the container prior to sealing thereof. Getters can be used to mitigate undesirable gases within the sealed container. One or more bolometers can be used to determine if the sealed container is leaking. A vacuum positioning fixture can be used to assemble the components of the infrared detector assembly and to place the infrared detector assemblies into a vacuum chamber. The cost of manufacturing such infrared detector assemblies may be reduced and the reliability thereof enhanced.Type: GrantFiled: March 20, 2006Date of Patent: December 30, 2008Assignee: Flir Systems, Inc.Inventors: Paul Schweikert, William J. Parrish, Andrew Sharpe, Vu L. Nguyen, Marco Scussat
-
Patent number: 7326682Abstract: The invention relates to an isolated, synthetic or recombinant ?-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.Type: GrantFiled: August 13, 2004Date of Patent: February 5, 2008Assignee: Xenome LimitedInventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe
-
Publication number: 20060276507Abstract: A class of piperidine and related heterocyclic derivatives, C-substituted by a substituted aryl or heteroaryl moiety, and N-substituted by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases.Type: ApplicationFiled: June 18, 2004Publication date: December 7, 2006Applicant: Celltech R&D LimitedInventors: David Owen, Robert Watson, Daniel Allen, Andrew Sharpe, Hazel Dyke
-
Publication number: 20060241118Abstract: A class of piperazine and related heterocyclic derivatives, substituted at the 4-position by a substituted aryl or heteroaryl moiety, and at the 1-position by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases.Type: ApplicationFiled: June 18, 2004Publication date: October 26, 2006Applicant: Celltech R&D LimitedInventors: David Owen, Robert Watson, Daniel Allen, Andrew Sharpe, Hazel Dyke
-
Patent number: 6849601Abstract: The present invention relates to novel peptides and derivatives thereof useful as selective ?1-adrenoceptor antagonists which ability of inhibiting the agonist action of agonist noradrenaline on the ?1-adrenoceptor is greater than their ability of inhibiting the action of agonist noradrenaline on the other ?-adrenoceptors. The invention also relates to pharmaceutical compositions comprising these peptides.Type: GrantFiled: October 1, 1999Date of Patent: February 1, 2005Assignee: The University of QueenslandInventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe
-
Publication number: 20040266764Abstract: The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.Type: ApplicationFiled: July 29, 2004Publication date: December 30, 2004Inventors: Duncan Robert Hannah, Hazel Joan Dyke, Andrew Sharpe, Andrew Douglas Baxter
-
Patent number: 6809100Abstract: The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.Type: GrantFiled: May 15, 2001Date of Patent: October 26, 2004Assignee: Darwin Discovery Ltd.Inventors: Duncan Robert Hannah, Hazel Joan Dyke, Andrew Sharpe, Andrew Douglas Baxter
-
Patent number: 6794361Abstract: The invention relates to an isolated, synthetic or recombinant &khgr;-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.Type: GrantFiled: June 27, 2001Date of Patent: September 21, 2004Assignee: The University of QueenslandInventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe